Zacks: Analysts Expect Panbela Therapeutics, Inc. (NASDAQ:PBLA) Will Announce Earnings of -$0.14 Per Share

Analysts expect that Panbela Therapeutics, Inc. (NASDAQ:PBLA) will report earnings of ($0.14) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Panbela Therapeutics’ earnings. Panbela Therapeutics posted earnings of ($0.09) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 55.6%. The company is expected to issue its next earnings report on Thursday, March 24th.

On average, analysts expect that Panbela Therapeutics will report full-year earnings of ($0.66) per share for the current year. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.66) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Panbela Therapeutics.

Panbela Therapeutics (NASDAQ:PBLA) last posted its earnings results on Wednesday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.11. During the same quarter in the prior year, the firm posted ($0.21) EPS.

Separately, Zacks Investment Research cut shares of Panbela Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday.

Several hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC purchased a new stake in shares of Panbela Therapeutics during the third quarter valued at about $72,000. Citadel Advisors LLC acquired a new position in Panbela Therapeutics in the 3rd quarter worth approximately $43,000. Goldman Sachs Group Inc. acquired a new position in Panbela Therapeutics in the 3rd quarter worth approximately $52,000. BlackRock Inc. grew its stake in shares of Panbela Therapeutics by 22.2% during the 3rd quarter. BlackRock Inc. now owns 29,359 shares of the company’s stock worth $64,000 after purchasing an additional 5,339 shares during the period. Finally, Warberg Asset Management LLC acquired a new stake in shares of Panbela Therapeutics during the 2nd quarter worth approximately $33,000. 8.28% of the stock is owned by institutional investors and hedge funds.

NASDAQ PBLA opened at $1.65 on Wednesday. Panbela Therapeutics has a 12 month low of $1.60 and a 12 month high of $8.80. The company’s 50 day moving average is $1.84 and its two-hundred day moving average is $2.24.

About Panbela Therapeutics

Panbela Therapeutics, Inc engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types.

Further Reading: Shanghai Stock Exchange Composite Index

Get a free copy of the Zacks research report on Panbela Therapeutics (PBLA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with's FREE daily email newsletter.